AU2017303333B2 - Sustained release composition comprising micronized tolcapone - Google Patents

Sustained release composition comprising micronized tolcapone Download PDF

Info

Publication number
AU2017303333B2
AU2017303333B2 AU2017303333A AU2017303333A AU2017303333B2 AU 2017303333 B2 AU2017303333 B2 AU 2017303333B2 AU 2017303333 A AU2017303333 A AU 2017303333A AU 2017303333 A AU2017303333 A AU 2017303333A AU 2017303333 B2 AU2017303333 B2 AU 2017303333B2
Authority
AU
Australia
Prior art keywords
tolcapone
tablet
cellulose
weight
tablet according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017303333A
Other languages
English (en)
Other versions
AU2017303333A1 (en
Inventor
Santiago ESTEVA GRAS
Oscar HUERTAS GAMBÍN
Raúl INSA BORONAT
Anna Nardi Ricart
Gal.La Pericot Mohr
Núria REIG BOLAÑO
Josep María SUÑÉ NEGRE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Som Innovation Biotech SA
Original Assignee
Som Innovation Biotech SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Som Innovation Biotech SA filed Critical Som Innovation Biotech SA
Publication of AU2017303333A1 publication Critical patent/AU2017303333A1/en
Application granted granted Critical
Publication of AU2017303333B2 publication Critical patent/AU2017303333B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2017303333A 2016-07-29 2017-07-28 Sustained release composition comprising micronized tolcapone Active AU2017303333B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16382372.7A EP3275433A1 (en) 2016-07-29 2016-07-29 Sustained release composition comprising micronized tolcapone
EP16382372.7 2016-07-29
PCT/EP2017/069168 WO2018019997A1 (en) 2016-07-29 2017-07-28 Sustained release composition comprising micronized tolcapone

Publications (2)

Publication Number Publication Date
AU2017303333A1 AU2017303333A1 (en) 2019-03-14
AU2017303333B2 true AU2017303333B2 (en) 2023-03-30

Family

ID=56571284

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017303333A Active AU2017303333B2 (en) 2016-07-29 2017-07-28 Sustained release composition comprising micronized tolcapone

Country Status (12)

Country Link
US (2) US11883538B2 (https=)
EP (2) EP3275433A1 (https=)
JP (1) JP7047236B2 (https=)
KR (1) KR102484678B1 (https=)
CN (1) CN109789100A (https=)
AU (1) AU2017303333B2 (https=)
DK (1) DK3490535T3 (https=)
ES (1) ES2891355T3 (https=)
MX (1) MX391116B (https=)
PT (1) PT3490535T (https=)
RU (1) RU2750670C2 (https=)
WO (1) WO2018019997A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024081554A2 (en) * 2022-10-10 2024-04-18 Corino Therapeutics, Inc. Modified release tolcapone formulations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100112053A1 (en) * 2007-01-15 2010-05-06 Kissei Pharmaceutical Co., Ltd. Gastric retention-type sustained-release levodopa preparation
US20140296188A1 (en) * 2011-10-24 2014-10-02 Som Innovation Biotech, S.L. New therapy for transthyretin-associated amyloidosis

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236952A (en) 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
BR9710448A (pt) * 1996-05-20 1999-08-17 Searle & Co Formula-{es farmac-uticas de sal de pot ssio sÄdioe tris oxaprozina
KR20010042566A (ko) 1998-04-09 2001-05-25 프리돌린 클라우스너, 롤란드 비. 보레르 압축된 기체 및 계면활성제중에 용해시킴으로써, 크기가마이크론 이하인 입자를 제조하는 방법
US6599530B2 (en) * 1998-09-14 2003-07-29 Orion Corporation Oral compacted composition comprising catechol derivatives
GB2348371B (en) * 2000-03-14 2001-04-04 Soares Da Silva Patricio Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
CA2510319A1 (en) * 2002-12-20 2004-07-15 Thomas J. Smith High pressure compaction for pharmaceutical formulations
EA013161B1 (ru) * 2005-06-08 2010-02-26 Орион Корпорейшн Дозированная форма для перорального применения
EP2640358B1 (en) 2010-11-15 2018-01-03 Neuroderm Ltd Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same
CA2835617C (en) 2011-03-14 2020-07-21 Boehringer Ingelheim International Gmbh Benzodioxane inhibitors of leukotriene production
US20130195973A1 (en) * 2012-01-30 2013-08-01 Ranbaxy Laboratories Limited Extended release pharmaceutical dosage forms of carbidopa and levodopa and process of preparation thereof
PT2968218T (pt) * 2013-03-13 2021-09-24 Neuroderm Ltd Combinação para tratamento da doença de parkinson
KR102457026B1 (ko) * 2013-11-05 2022-10-21 신애질 코포레이션 입을 통한 연속적 약물 전달
PT3782617T (pt) * 2014-09-04 2024-02-29 Lobsor Pharmaceuticals Ab Composições farmacêuticas de gel compreendendo levodopa, carbidopa e entacapona

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100112053A1 (en) * 2007-01-15 2010-05-06 Kissei Pharmaceutical Co., Ltd. Gastric retention-type sustained-release levodopa preparation
US20140296188A1 (en) * 2011-10-24 2014-10-02 Som Innovation Biotech, S.L. New therapy for transthyretin-associated amyloidosis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Rote Liste 2012", 2 January 2012, article UNKNOWN: "Tasmar 100mg", XP055331811 *

Also Published As

Publication number Publication date
US12220487B2 (en) 2025-02-11
EP3275433A1 (en) 2018-01-31
BR112019001826A2 (pt) 2019-05-07
KR102484678B1 (ko) 2023-01-03
JP2019523305A (ja) 2019-08-22
RU2750670C2 (ru) 2021-06-30
RU2019103647A3 (https=) 2020-10-12
PT3490535T (pt) 2021-09-30
DK3490535T3 (da) 2021-10-04
EP3490535A1 (en) 2019-06-05
ES2891355T3 (es) 2022-01-27
RU2019103647A (ru) 2020-08-28
WO2018019997A1 (en) 2018-02-01
CA3032211A1 (en) 2018-02-01
MX2019001190A (es) 2019-09-06
US11883538B2 (en) 2024-01-30
JP7047236B2 (ja) 2022-04-05
EP3490535B1 (en) 2021-07-14
KR20190034563A (ko) 2019-04-02
MX391116B (es) 2025-03-21
AU2017303333A1 (en) 2019-03-14
CN109789100A (zh) 2019-05-21
US20190167596A1 (en) 2019-06-06
US20240216282A1 (en) 2024-07-04

Similar Documents

Publication Publication Date Title
JP4757872B2 (ja) プラミペキソール又はその医薬品として許容される塩を含む放出が延長された錠剤調合物、その製造方法及びその使用
CA2956527C (en) Directly compressible polyvinyl alcohols
JP6706245B2 (ja) 微結晶性セルロースを含む直接圧縮可能な組成物
AU2014225449B2 (en) Stabilization of moisture-sensitive drugs
US12551486B2 (en) Rivaroxaban formulation
US12220487B2 (en) Sustained release compositions comprising micronized tolcapone
CA3032211C (en) Sustained release composition comprising micronized tolcapone
JP6002869B1 (ja) ジエノゲスト含有錠剤
JP6918393B1 (ja) 漢方エキス又は植物性生薬エキスを含む固形製剤及びその製造方法、並びに固形製剤の崩壊性を向上させる方法
BR112019001826B1 (pt) Composição de liberação prolongada compreendendo tolcapone micronizada
JPH02282322A (ja) 有効物質の浸食制御による放出システムおよびその製造方法
JP2017075138A (ja) ジエノゲスト含有錠剤
HK40008562A (en) Sustained release composition comprising micronized tolcapone
JP2676305B2 (ja) シタラビンオクホスファート硬カプセル剤
WO2021148362A1 (en) Directly compressible polymer combinations for matrix tablets with extended drug release
WO2017064815A1 (ja) 低用量薬物を含有する口腔内崩壊錠
GB2491205A (en) Composition comprising bosentan and diluents

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)